Dr. Andrea Weiland-Waibel

Managing Director at Explicat Pharma GmbH
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Bavaria, Germany, DE
Languages
  • German Native or bilingual proficiency
  • English Full professional proficiency
  • French Professional working proficiency
  • Spanish Elementary proficiency
Skills

Topline Score

Bio

Generated by
Topline AI

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.
You need to have a working account to view this content. Click here to join now

Credentials

  • QVM 1 - GMP für Medizinprodukte
    CONCEPT HEIDELBERG GmbH
    Feb, 2020
    - Sep, 2024
  • ECA - Combination Products
    ECA European Compliance Academy
    Jan, 2020
    - Sep, 2024

Experience

  • Explicat Pharma GmbH
    • Germany
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Managing Director
      • 2005 - Present

    • Owner
      • 2005 - 2005

      see www.explicat.com

  • IDEA AG
    • Brazil
    • Advertising Services
    • 1 - 100 Employee
    • Director Pharmaceutical Development
      • Apr 1999 - Dec 2001

      Formulation and Analytical Development clinical supplies manufacture - liposomes, micelles QP Formulation and Analytical Development clinical supplies manufacture - liposomes, micelles QP

  • Pfizer R&D
    • United States
    • Hospitals and Health Care
    • Head of Development
      • Apr 1998 - Apr 1999

      Head of Pharmaceutical Technology Lab Process Qualification and Development - Sterile Lyophile (multinational project) Development of Clinical Supplies for Clinical Studies, solid dosage, sustained release Head of Pharmaceutical Technology Lab Process Qualification and Development - Sterile Lyophile (multinational project) Development of Clinical Supplies for Clinical Studies, solid dosage, sustained release

  • Pfizer-Gödecke Freiburg Germany
    • Project Manager Process Technology
      • Feb 1995 - Mar 1998

      Scale up/Validation Activities Sustained Release Tablet Development Scale up/Validation Activities Sustained Release Tablet Development

  • Ludwig-Maximilians-Universität (LMU) München
    • PHD Student
      • Jan 1991 - Jan 1995

      Ph.D. Student/Assistant at Ludwig Maximilians University Munich/Dept. Pharmaceutical Technology Ph.D. Thesis Formulation, Manufacture and Characterization of Biodegradable Microspheres from Poly(D,L-lactide-co-Glycolide) and Cyclodextrin-complexes with Bupivacain-Hydrochloride for parenteral sustained release forms Ph.D. Student/Assistant at Ludwig Maximilians University Munich/Dept. Pharmaceutical Technology Ph.D. Thesis Formulation, Manufacture and Characterization of Biodegradable Microspheres from Poly(D,L-lactide-co-Glycolide) and Cyclodextrin-complexes with Bupivacain-Hydrochloride for parenteral sustained release forms

  • Flora Pharmacy
    • United States
    • Personal Care Product Manufacturing
    • 1 - 100 Employee
    • Internship
      • May 1990 - Oct 1990

      work in pharmacy work in pharmacy

  • Klinge Pharma/Fujisawa
    • Internship
      • Sep 1989 - Apr 1990

      Worked in production, pharmaceutical development, QC, QA and Biopharmaceutical/Bioavailability Departments Worked in production, pharmaceutical development, QC, QA and Biopharmaceutical/Bioavailability Departments

Education

  • Ludwig-Maximilians-Universität München
    Ph.D., Pharmaceutical Technology
    1985 - 1995

Community

You need to have a working account to view this content. Click here to join now